First Trust Advisors’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-6,405
| Closed | -$1.1M | – | 2663 |
|
|
2021
Q3 | $1.1M | Sell |
6,405
-77,007
| -92% | -$10.1M | ﹤0.01% | 1996 |
|
|
2021
Q2 | $10.5M | Sell |
83,412
-73,349
| -47% | -$9.25M | 0.01% | 994 |
|
|
2021
Q1 | $21.3M | Sell |
156,761
-20,543
| -12% | -$2.65M | 0.03% | 688 |
|
|
2020
Q4 | $22.7M | Sell |
177,304
-14,739
| -8% | -$1.73M | 0.03% | 588 |
|
|
2020
Q3 | $21.6M | Buy |
192,043
+150,982
| +368% | +$15M | 0.03% | 517 |
|
|
2020
Q2 | $3.91M | Sell |
41,061
-2,675
| -6% | -$258K | 0.01% | 1077 |
|
|
2020
Q1 | $3.93M | Buy |
43,736
+35,650
| +441% | +$2.77M | 0.01% | 961 |
|
|
2019
Q4 | $429K | Buy |
+8,086
| New | +$369K | ﹤0.01% | 2160 |
|
|
2019
Q2 | – | Sell |
-16,238
| Closed | -$756K | – | 2543 |
|
|
2019
Q1 | $756K | Sell |
16,238
-17,445
| -52% | -$766K | ﹤0.01% | 1971 |
|
|
2018
Q4 | $1.47M | Sell |
33,683
-11,445
| -25% | -$572K | ﹤0.01% | 1638 |
|
|
2018
Q3 | $2.58M | Buy |
+45,128
| New | +$2.22M | ﹤0.01% | 1518 |
|
|
2018
Q2 | – | Sell |
-32,354
| Closed | -$1.26M | – | 2503 |
|
|
2018
Q1 | $1.26M | Buy |
32,354
+17,176
| +113% | +$730K | ﹤0.01% | 1694 |
|
|
2017
Q4 | $644K | Buy |
+15,178
| New | +$569K | ﹤0.01% | 2012 |
|
|
2017
Q1 | – | Sell |
-48,251
| Closed | -$1.23M | – | 2482 |
|
|
2016
Q4 | $1.23M | Buy |
48,251
+16,718
| +53% | +$530K | ﹤0.01% | 1738 |
|
|
2016
Q3 | $1.14M | Buy |
+31,533
| New | +$1.04M | ﹤0.01% | 1630 |
|
First Trust Advisors's XLRN Position: Q4 2021 in Review
First Trust Advisors sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 6,405 shares — an estimated $1.1M sold.
First Trust Advisors first reported a position in XLRN in Q3 2016 and held it in 15 quarters. The position peaked at $22.7M in Q4 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- First Trust Advisors reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- First Trust Advisors sold 6,405 Acceleron Pharma shares in Q4 2021, an estimated $1.1M.
- First Trust Advisors first reported a position in Acceleron Pharma in Q3 2016 and held it in 15 quarters.
- First Trust Advisors's Acceleron Pharma position peaked at $22.7M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on First Trust Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.